A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM)

Autor:	Lowell L. Hart, Rami Owera, Jeffrey Matous, Edward A. Faber, Tara K. Gregory, James Essell, Jesus G. Berdeja, Ian W. Flinn, Joseph R. Mace
Rok vydání:	2015
Předmět:	Cancer Research business.industry medicine.disease Carfilzomib chemistry.chemical_compound Aggresome Oncology chemistry Proteasome Panobinostat Relapsed refractory medicine Cancer research In patient Histone deacetylase business Multiple myeloma
Zdroj:	Journal of Clinical Oncology. 33:8513-8513
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2015.33.15_suppl.8513
Popis:	8513 Background: Histone deacetylase inhibitors (HDACi) and proteasome inhibitors (PI) act synergistically through inhibition of the proteasome and aggresome pathways. We have previously reported t...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4ade03ea06f85f7b10a84c01b5d29dae https://doi.org/10.1200/jco.2015.33.15_suppl.8513 Zobrazit plný text záznamu